Skip to main content
Premium Trial:

Request an Annual Quote

Genetix s QTray and OriGene Technologies Cytochrome P450 CloneSet


Genetix has announced the launch of QTray, its newest bioassay tray.

The QTray is designed for large-scale culture and screening of bacterial and yeast libraries, and has been redeveloped with a focus on convenience and facilitation of rapid workload management, the company said.

The product features vents beneath its lid to avoid condensation formation, and has level fill lines around the tray base to facilitate media pouring without prior measurement.

In addition, the company said, the QTray has a large surface area and is automation-compatible.

OriGene Technologies has added the cytochrome P450 CloneSet, a complete set of more than 60 full-length cytochrome P450 cDNA clones, to its TrueClone product line.

Cytochrome P450 proteins are a family of mono-oxygenases critical for drug metabolism and the degradation of environmental toxins and mutagens, the company said.

The TrueClone collection of 22,000 full-length cDNAs includes over 75 percent of the NM sequences in the NCBI RefSeq database, the company said, and covers 65 to 80 percent of the predicted human cDNA repertoire.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.